Quantum BioPharma Begins Phase 2 Lucid-MS Trial Start-Up

Quantum BioPharma has formally initiated study start-up activities for its Phase 2 clinical trial of Lucid-MS. The company contracted the PPD clinical research business of Thermo Fisher Scientific to oversee the program. This development follows recent FDA clearance to test the drug candidate in patients with progressive forms of multiple sclerosis.

"We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2. Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step," said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma, in a statement.

Trial Design and Clinical Objectives

The upcoming trial is a randomized, double-blind, placebo-controlled study. The primary objectives are to evaluate the efficacy, safety, and tolerability of Lucid-MS in a patient population dealing with progressive multiple sclerosis, a condition characterized by the gradual worsening of neurological function.

Many existing MS treatments focus on modulating the immune system to prevent relapses. Lucid-MS is a patented chemical entity designed to target demyelination directly. Its mechanism of action centers on a neuroprotective approach to preserve or repair the protective sheath surrounding nerve fibers, which is typically damaged in MS patients.

What Is at Stake for Patients

The move to Phase 2 marks a transition in the drug development lifecycle. Phase 1 studies assess safety and dosage in a small group of participants. Phase 2 trials provide initial evidence of clinical efficacy. For patients with progressive MS, current treatment options are limited because many approved therapies manage relapsing-remitting forms of the disease rather than the steady decline associated with progressive variants.

By engaging a contract research organization with experience in central nervous system conditions, Quantum BioPharma is preparing for the logistical demands of multi-site clinical operations. The start-up phase involves final protocol adjustments, site selection, and regulatory filings necessary to begin patient enrollment.